Premium
Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology
Author(s) -
Sattlecker Martina,
Kiddle Steven J.,
Newhouse Stephen,
Proitsi Petroula,
Nelson Sally,
Williams Stephen,
Johnston Caroline,
Killick Richard,
Simmons Andrew,
Westman Eric,
Hodges Angela,
Soininen Hilkka,
Kłoszewska Iwona,
Mecocci Patrizia,
Tsolaki Magda,
Vellas Bruno,
Lovestone Simon,
Dobson Richard J.B.
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2013.09.016
Subject(s) - entorhinal cortex , atrophy , biomarker , clusterin , context (archaeology) , alzheimer's disease , hippocampus , disease , medicine , biology , neuroscience , endocrinology , oncology , psychology , biochemistry , apoptosis , paleontology
Blood proteins and their complexes have become the focus of a great deal of interest in the context of their potential as biomarkers of Alzheimer's disease (AD). We used a SOMAscan assay for quantifying 1001 proteins in blood samples from 331 AD, 211 controls, and 149 mild cognitive impaired (MCI) subjects. The strongest associations of protein levels with AD outcomes were prostate‐specific antigen complexed to α1‐antichymotrypsin (AD diagnosis), pancreatic prohormone (AD diagnosis, left entorhinal cortex atrophy, and left hippocampus atrophy), clusterin (rate of cognitive decline), and fetuin B (left entorhinal atrophy). Multivariate analysis found that a subset of 13 proteins predicted AD with an accuracy of area under the curve of 0.70. Our replication of previous findings provides further evidence that levels of these proteins in plasma are truly associated with AD. The newly identified proteins could be potential biomarkers and are worthy of further investigation.